Company intelligence / Profile preview

Broad Well

Austin, Texas, United States

Ownership: Private
Development stage: Other

Overview

Broadwell Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for rare metabolic diseases. The company's lead asset is pegzilarginase, a recombinant human arginase 1 enzyme therapy designed to lower elevated arginine levels in patients with Arginase 1 Deficiency (ARG1-D). Broadwell acquired the global rights to pegzilarginase from Aeglea BioTherapeutics in 2023 following positive results from the Phase 3 PEACE trial. The company is dedicated to addressing high unmet medical needs through the development of enzyme-based treatments. Broadwell is currently working with regulatory agencies to advance pegzilarginase toward commercialization in major global markets.

Therapeutic areas: Metabolic Disorders
Modalities: Recombinant proteinEnzyme replacement therapy
Industry: Biotech

Beyond the preview

Go deeper on Broad Well.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Broad Well.

Explore the full profile